Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina (T89 phase 2)

Tasly Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Angina Pectoris

Treatments: Drug: T89

Study type: Interventional

Funder types: Industry

Identifiers

NCT00797953

T89-005-0003-US

Details and patient eligibility

About

The purpose of this study is to determine the anti-angina effect and dose response of T89, a 2-herb botanical drug product, in patients with chronic stable angina pectoris in the United States.

Full description

T89 is a modernized and industrialized version of a traditional Chinese herbal medicine. T89 was approved for marketing as a drug, for the treatment of chronic stable angina pectoris due to coronary heart disease, by the State Food and Drug Administration (SFDA) of China in 1993. There were more than 2 billion doses have been prescribed or used, in about 10,000,000 subjects, in short or long-term administration worldwide.

The product is also marketed, as a drug, in Russia, South Korea, Mongolia, Singapore, Vietnam, and South Africa. The current study is to determine the anti-angina effect and dose response of T89 in patients with chronic stable angina pectoris in the United States.

T89 consists of Danshen (Radix Salviae Miltiorrhizae, RSM) and Sanqi (Radix Notoginseng, RN) as active constitutes, and using Borneol as transporting enhancer.

Enrollment: 124 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patient must be between the ages of 18 and 80 years.
2. Females of childbearing potential must have a negative pregnancy test, not be breast feeding and established on a method of contraception that in the investigator's opinion is acceptable. Females must agree to remain on their established method of contraception through their participation in the study.
3. Evidence of coronary artery disease that consists of a well-documented medical history (over 3 months prior to the enrollment) of myocardial infarction or significant coronary artery disease with noninvasive or angiographic confirmation.
4. Symptoms that support the diagnosis of chronic angina and/or a history of an abnormal exercise response limited by angina and/or electrocardiograph (ECG) changes.
5. Moderate angina pectoris (Class II or Class III, Grading of Angina Pectoris by the Canadian Cardiovascular Society Classification System)
6. Naive patient or patient who's Total Exercise Duration (TED) is between 3 to 7 minutes in ETT on Standard Bruce Protocol, and the difference in TED must be no more than 15% between the two screen examinations on day -7 and day 0
7. All anti-angina regimen (except short-acting nitroglycerin, and one beta-blocker or calcium channel blocker), warfarin or other oral anticoagulants which were used prior to this initial visit can be discontinued.
8. Patient must understand and be willing, able and likely to comply with all study procedures and restrictions and comprehends the verbal rating scales and diary cards.
9. Patient must be able to give voluntary written informed consent.

Exclusion criteria

1. With contraindication to perform treadmill Exercise Tolerance Test (ETT).

2. Pre-exercise ST-segment depression of at least 1 mm in any lead, left bundle branch block, digoxin therapy, Left Ventricular Hypertrophy (LVH) and Wolff-Parkinson-White (WPW) syndrome or other factors that could interfere with exercise electrocardiograph interpretation.

3. Clinically significant arrhythmias or atrioventricular conduction block greater than first degree.

4. Clinically significant co-morbidities, including hepatic or renal dysfunction, pulmonary hypertension, chronic obstructive pulmonary disease, history of cerebral hemorrhage, or seizure disorders that required anticonvulsant medication.

5. History of congestive heart failure, unstable angina, severe valvular disease, severe hypertension, severe anemia, suspected or known dissecting aneurysm, acute myocarditis or pericarditis, thrombophlebitis or pulmonary embolism or recent myocardial infarction within three months of study entry.

6. History of bleeding diathesis, or is on warfarin.

7. Implanted pacemaker.

8. Aspirin and/or statins started less than 14 days prior to the signing of informed consent.

9. Pregnancy or lactation.

10. Inability to discontinue existing chronic nitrate regimen (e.g. long acting nitroglycerin) and allow only short-acting nitroglycerin and one beta-blocker or calcium channel blocker.

11. Clinical trials/experimental medication:

    • Participation in any other clinical trial or receipt of an investigational drug within 90 days prior to initial visit.
    • Those patients unable, in the opinion of the investigator, to comply fully with the trial requirements.
    • Previous participation in this study.

12. Substance abuse. Patients with a recent history (within the last 2 years) of alcoholism or known drug dependence.

13. Patient is a family member or relative of the study site staff.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

124 participants in 3 patient groups, including a placebo group

Low dose

Experimental group

Description:

2 capsules of T89 with 1 placebo capsule each time, twice daily. The daily dose is 250 mg.

Treatment:

Drug: T89

High dose

Experimental group

Description:

3 capsules of T89 each time, twice daily. The daily dose is 375 mg

Treatment:

Drug: T89

Placebo

Placebo Comparator group

Description:

3 placebo capsules (PC) each time, twice per day. The daily dose is 0 mg.

Treatment:

Drug: T89